Immuneering (US:IMRX) Seeking Alpha·2026-01-07 23:47Core Insights - The conference call discusses the positive 12-month overall survival update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] Group 1: Company Overview - Immuneering's leadership team includes Co-Founder and CEO Ben Zeskind, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Matushansky, Chief Accounting Officer and Treasurer Mallory Morales, and Chief Business Officer E.B Brakewood [2] Group 2: Trial Information - The call will include forward-looking statements regarding the Phase IIa trial of atebemetinib, including the timing of additional data and the company's development plans [3] - Actual results and timing of events may differ materially from anticipated outcomes due to various risks and uncertainties [4]